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Background: The mechanisms of lipid raft regulation by microRNAs in breast cancer are not fully understood.
This work focused on the evaluation and identification of miR-3908, which may be a potential biomarker related
to the migration of breast cancer cells, and elucidates lipid-raft-regulating cell migration in breast cancer.
Methods: To confirm the prediction that miR-3908 is matched with AdipoR1, we used 3’-UTR luciferase activity of
AdipoR1 to assess this. Then, human breast cancer cell line MCF-7 was cultured in the absence or presence of the
mimics or inhibitors of miR-3908, after which the biological functions of MCF-7 cells were analyzed. The protein
expression of AdipoR1, AMPK, and SIRT-1 were examined. The interaction between AdipoR1 and Flotillin-1, or its
effects on lipid rafts on regulating cell migration of MCF-7, was also investigated.
Results: AdipoR1 is a direct target of miR-3908. miR-3908 suppresses the expression of AdipoR1 and its downstream
pathway genes, including AMPK, p-AMPK, and SIRT-1. miR-3908 enhances the process of breast cancer cell
clonogenicity. miR-3908 exerts its effects on the proliferation and migration of MCF-7 cells, which are
mediated by lipid rafts regulating AdipoR1’s ability to bind Flotillin-1.
Conclusions: miR-3908 is a crucial mediator of the migration process in breast cancer cells. Lipid rafts
regulate the interactions between AdipoR1 and Flotillin-1 and then the migration process associated with
miR-3908 in MCF-7 cells. Our findings suggest that targeting miR-3908 and the lipid raft, may be a promising
strategy for the treatment and prevention of breast cancer.
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Currently, the diagnosis of BC (breast cancer) is increas-
ing rapidly, and has now reached epidemic proportions;
half a million deaths occur from BC every year [1].
Worldwide, as a major public health problem, it nega-
tively affects the quality of life of several millions of pa-
tients and their families [2]. Rapidly increasing incidence
and prevalence rates of BC are dramatic, and are the
new social challenge [3–6].* Correspondence: dtzlzx@sina.com
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(http://creativecommons.org/publicdomain/zeLipid rafts orchestrate molecular interactions and are
microdomains of dynamic membranes and are involved
in carcinogenesis, especially BC [7]. Shah et al. have per-
formed a general analysis on modeling progression in
BC based on quantitatation of lipid rafts with proteomic
datasets [7]. Their results indicated that the develop-
ment of carcinoma is related to increase in the interac-
tions between cell cytoskeleton and membrane raft; the
proteins of the lipid raft constitute almost 40% of the
cytoskeleton [7]. Moreover, compared with common
human raft proteins, the interaction network among
proteins in the simulation analysis revealed obviously
higher interactions between raft proteins of cancer cells.
The stabilization of domains in the lipid raft was shownle is distributed under the terms of the Creative Commons Attribution 4.0
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skeleton, and showed the reversible, functional, and
common features in cancer cells through greater mo-
lecular interactions [8]. Recent researches have sug-
gested the potential functional role associated with the
raft cytoskeleton and tumor suppressors Flotillin-1 and
AdipoR1.
A lipid raft is composed dynamically of lipids and pro-
teins and numerous assembled regulatory molecules and
receptors which then enable it to be regarded as the
platform for signal transduction [8]. It can also form lar-
ger orderly domains, and freely float within the cellular
membranes between a liquid disordered bilayer. Alter-
ations of lipid rafts are identified and can be related to
many human diseases, and microRNAs (miRNAs) can
also perturb the domains of the lipid raft through target-
ing its proteins [9, 10]. In the past few years, the signifi-
cance of the relationship between the lipid raft and BC
has been elucidated [11–13].
The growing medical literature supports the vital func-
tion of miRNAs in gene expression regulation. The miR-
NAs are a group of tiny molecules and noncoding
ribonucleic acid (RNA), 22 to 25 nucleotides in length,
that function in post-transcriptional-level regulation of
gene expression [14]. miRNAs control gene expression
by pairing with incompletely matching target sites of the
3’-untranslated regions (UTRs) of messenger RNA
(mRNA), and cause translational repression and/or
mRNA destabilization, thereby downregulating the ex-
pression of the targeted gene. The regulated expression
of genes is involved in numerous biological progressions,
especially for the various disorders of pathogenesis (in-
cluding cancer progression) [15–18]. We found that
miR-3908 is expressed in the human breast cancer cell
line MCF-7.
Adiponectin (APN), an adipokine produced by adipo-
cytes, has been shown to play a critical role in the patho-
genesis of obesity-associated malignancies. Through its
receptor interactions, APN may exert its anti-
carcinogenic effects, including regulating cell survival,
apoptosis, and metastasis, via a plethora of signaling
pathways [19]. Miyoshi et al. [20] first highlighted the re-
lationship between hypoadiponectinemia and increased
BC risk, where BC patients with lower APN levels are
more likely to show a more aggressive phenotype. A re-
cent meta-analysis of observational studies found that
low APN levels are associated with increased risk of BC
in postmenopausal, but not premenopausal women [21].
The risk reduction from higher APN levels has been re-
ported to be around 65–80% in early BC patients [22].
To assess the role of miR-3908 in human MCF-7 cells,
we first identified whether miR-3908 sequences are
present in AdipoR1 mRNA. Our work firstly demon-
strated that AdipoR1 is one of the targets of miR-3908which regulates the expression of AdipoR1 followed by
regulation of the AMPK/SIRT-1 signaling pathway.
AdipoR1 may control the migration of MCF-7 cells me-
diated by the lipid raft through regulating the interaction
between AdipoR1 and Flotillin-1. We, therefore, investi-
gated the effect of miR-3908 on regulating the inter-
action between AdipoR1 and Flotillin-1 in MCF-7 cells.
In particular, the cell migration effects of miR-3908 have
been associated with the regulation of the lipid raft and
the AdipoR1-AMPK/SIRT-1 signaling pathway.
Methods
Cell culture
MCF-7 cells were obtained from the American Type
Culture Collection (ATCC), and then cultured with
Dulbecco’s modified Eagle’s medium (DMEM) and fetal
bovine serum (FBS) (Gibco), penicillin, and streptomycin
at 37 °C in an atmosphere with 5% CO2.
Extracting total RNA and cloning novel miRNA
Total cell RNA was obtained using the TRIzol method
(Sigma, Palo Alto, CA, USA), based on the manufac-
turer’s protocol. Total RNAs were isolated with a mir-
Vana RNA Isolation Kit and the RNA fragments smaller
than 200 nt were eliminated. The miR-3908 was cloned
into the open-code frame vector using a DynaExpress
miRNA Cloning Kit based on its manufacturer’s instruc-
tions, and then modified.
Reporter gene assays
The complementary deoxyribonucleic acids (cDNAs) en-
coding the entire 3’-UTR of AdipoR1 mRNAs were pre-
dicted and amplified from the total RNA of MCF-7 cells
using Xho I and Not I linker/primers, and then cloned
into the vector pmirGLO (the luciferase reporter vector)
that included the gene that expresses firefly luciferase
and Renilla luciferase. AdipoR1 3’-UTRs was cloned in
reverse orientation as controls lacked the miRNA target
sequence [23]. Additionally, the complementary region
to the seed region of the miR-3908 sequence located in
positions 139–146 of human AdipoR1 3’-UTR, CAUUG-
CUA. These constructs were all identified using COS-7
cells (gift from Dr. Feng Liu, Chinese Academy of Sci-
ences), which were transfected with the reporter con-
struct and the indicated miRNA mimic or its negative
control sequences using Lipofectamine 3000 (Invitrogen,
Carlsbad, CA, USA). The activity of Renilla luciferase
was normalized with the corresponding control of the
Dual-Glo® Luciferase Assay System. The mutant con-
struct of the AdipoR1-3’-UTR was created with the Site-
Mutation kit (Promega, Madison, WI, USA). Then, ei-
ther negative control (NC) or miR-3908 were co-
transfected into cells. Analysis of the luciferase activity
of cells was detected with the VICTOR analyzer
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periments regarding AMPK, SIRT-1, and Flotillin-1 were
performed as above.
The mimics of miR-3908 and transfection
Transfection with mimics of miR-3908 was performed
using Lipofectamine 3000 (Sigma, Palo Alto, CA, USA)
based on the manufacturer’s protocol. The mimics of
miR-3908 were as follows: sense 5’-AAGGGAAGAUGG
UGACCACUU-3’ and antisense 5’-AAGUGGUCACCA
UCUUCCCUU-3’. The inhibitors of miR-3908 were as
follow: 5’-GUGGUCACCAUCUUCCCUU-3’. Moreover,
the NC was as follows: sense 5’-ACGUGACACGUUCG
GAGAAUU-3’ and antisense 5’-AAUUCUCCGAACGU
GUCACGU-3’ which was not homologous with the
human genome sequences. qRT-PCR was used to iden-
tify the dose effect of miR-3908.
qRT-PCR analysis
We identified the expression pattern of miR-3908 in MCF-7
cells according to the TaqMan miRNA assays with its specific
primers. The 2−ΔΔCt method was used to analyze the data.
qRT-PCR was performed with a SYBR Green kit (Sigma, Palo
Alto, CA, USA). The primer sequences were as follows:
AdipoR1 upstream 5’-CAGATTTTCCATGTCCTGGTG-3’
and downstream 5’-CGGAATTCCTGAAGGTTGG-3’; and




Cells were lysed, and then total proteins were extracted
with radioimmunoprecipitation assay (RIPA) lysis buffer.
Total proteins were analyzed with an electrophoresis
method using sodium dodecyl sulfate-polyacrylamide
(SDS-PAGE) gel, and then transferred to a polyvinylidene
fluoride (PVDF) membrane with a 0.45-μm pore size
(Roche, Branchburg, NJ, USA). This process was prohib-
ited with 5% skimmed milk and the preparation then
washed three times with Tris-buffered saline (TBST) at
room temperature, and then at 4 °C, and probed with the
antibodies: AdipoR1, SIRT-1, AMPK (1:4000, Cell Signal-
ing, Danvers, MA, USA), p-AMPK, Flotillin-1, β-actin
(1:2000, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
overnight. Finally, the preparation was incubated at room
temperature with proper secondary antibodies (1:5000 di-
lutions, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Analysis of proliferation and clonogenicity in MCF-7 cells
Cell proliferation ability was detected with an MTS
assay. With crystal violet, the colonies of cells were
stained, and then fixed by formalin. The clonogenicity
assay could demonstrate the quantity of developed cell
colonies which differs from other methods.Cell migration assay
The migration ability of MCF-7 cells was measured
using a wound scratch assay. Cells were first scratched,
and then their movements were observed and measured
at 48 h. The migratory cells were counted and their total
number quantified.
Co-immunoprecipitation
Five microliters phenylmethanesulfonyl fluoride (PMSF)
was added to the cultured cells, and then the cells were
lysed. To each supernatant from the cell extraction was
added 50 μL Protein G Plus/Protein A Agarose Suspen-
sion (Calbiochem, San Diego, CA, USA). Ten microliters
anti-AdipoR1 or anti-Flotillin-1 antibody was added into
the supernatants which were rotated gently overnight,
respectively. Sixty microliters Protein G Plus/Protein A
Agarose Suspension was then added to the samples,
which were then rotated gently for 9 h at 4 °C and finally
centrifuged for 5 min. Immunoprecipitates were washed
and resuspended with loading buffer before boiling or
electrophoresis, then resolved by SDS-PAGE; anti-
Flotillin-1 and anti-AdipoR1 antibody were used for
immunoblotting, respectively.
Confocal laser scanning
The cDNA sequences of AdipoR1 and Flotillin-1 were
cloned into the pDS-RED1-N1 or pEGFP-C1 expression
vector, respectively. The pEGFP-C1-Flotillin-1 and pDS-
RED1-N1-AdipoR1 vectors were then co-transfected
into MCF-7 cells. After transfection for 48 h, cells were
treated with 4% paraformaldehyde, and then stained with
DAPI (4’,6-diamidino-2-phenylindole). These cells were
then observed with a LSM 510 microscope (Zeiss,
Oberkochen, Germany).
Purification of membrane and lipid raft protein
Membrane proteins were isolated from MCF-7 cells by a
multiple-centrifugation procedure [24]. Lipid raft
fractions were purified from MCF-7 cells by a modified
sucrose density gradient ultracentrifugation procedure
[25, 26]. Briefly, MCF-7 cells were lysed with ice-cold
MBS buffer. The lysates were mixed with sucrose and
ultracentrifuged for 18 h at 39,000 rpm, then the sam-
ples were separated to 12 subfractions [27].
Statistical analyses
Statistical differences between groups were analyzed
with a two-tailed, paired Student t test. Data for qRT-
PCR and luciferase reporter assays were expressed
relative to the control in each experiment, and 95% con-
fidence intervals were calculated. Continuous variables
were shown with mean ± SD (standard deviation).
Between groups, abnormally distributed data were ana-
lyzed using a Kruskal-Wallis analysis of variance
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SPSS software (SPSS Inc., Chicago, IL, USA; version
18.0). P < 0.05 was regarded as statistically significant.
Results
Expression of AdipoR1 was suppressed by miR-3908 in
MCF-7 cells
To explore whether miRNA regulates AdipoR1, or the
upward pathway of AdipoR1 in MCF-7 cells, firstly we
used the online software Targetscan (http://targetscan.
org/) to forecast miRNAs that target AdipoR1. WithinFig. 1 Expression of AdipoR1 was suppressed by miR-3908 in MCF-7 cells.
of AdipoR1 in MCF-7 cells, firstly, using the online software Targetscan (http
Within these miRNAs, miR-3908 potentially co-targeted mRNAs of AdipoR1
reporter gene assay to identify whether 3’-UTRs of AdipoR1 were bonded d
activities of AdipoR1 3’-UTR were obviously downregulated in MCF-7 ce
the mut-AdipoR1 group (b). However, it was identified that miR-3908 c
(e) 3’-UTRs, respectively. The data are presented as means ± SD from ththese miRNAs, miR-3908 potentially co-targeted the
mRNAs of AdipoR1 3’-UTRs. A further proof experi-
ment was carried out with a luciferase reporter gene
assay, to identify whether 3’-UTRs of AdipoR1 were
bonded directly with miR-3908. The results showed that
the relative luciferase activities of AdipoR1 3’-UTR were
obviously downregulated in MCF-7 cells transfected with
miR-3908 (Fig. 1a), but there was no change in the mut-
AdipoR1 group (Fig. 1b). However, it was identified that
miR-3908 could not form direct bonds with AMPK
(Fig. 1c), SIRT-1 (Fig. 1d), or Flotillin-1 (Fig. 1e) 3’-To study if microRNA modulates AdipoR1, or the downstream pathway
://targetscan.org/), we tried to forecast miRNAs that target AdipoR1.
3’-UTRs. A further proof experiment was carried out with a luciferase
irectly with miR-3908. The results showed that the relative luciferase
lls transfected with miR-3908 (a), but there was no change in
ould not form direct bonds with AMPK (c), SIRT-1 (d), or Flotillin-1
ree independent experiments. *P < 0.05, **P < 0.01
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could directly target the mRNAs of AdipoR1.
To confirm the miR-3908 effect on the mRNA and
protein expression of AdipoR1, AMPK, SIRT-1, and
Flotillin-1 in MCF-7 cells, we accomplished relative
quantification analyses with qRT-PCR and Western
blots, respectively (Fig. 2). The results indicated that
miR-3908 inhibited the mRNA expression of AdipoR1 in
MCF-7 cells (Fig. 2a), as well as the protein expression
of AdipoR1 (Fig. 2b). Moreover, miR-3908 did not affect
the mRNA expression of AMPK, SIRT-1, and Flotillin-1,
but the protein expression of AMPK, p-AMPK, SIRT-1,
and Flotillin-1 also decreased (Fig. 2b). Furthermore, the
inhibitors of miR-3908 promoted the mRNA expression
of AdipoR1 in MCF-7 cells, but did not affect the mRNA
expression level of SIRT-1, AMPK, and Flotillin-1
(Fig. 2a). Altogether, our results demonstrated that miR-
3908 directly regulates the expression of AdipoR1 byFig. 2 Expression of AdipoR1 was suppressed by miR-3908 in MCF-7 cells.
AdipoR1, AMPK, SIRT-1, and Flotillin-1 in MCF-7 cells, we accomplished relativ
miR-3908 inhibited the mRNA expression of AdipoR1 in MCF-7 cells (a), as we
affect the mRNA expression of AMPK, SIRT-1, and Flotillin-1, but the protein ex
Furthermore, the inhibitors of miR-3908 promoted the mRNA expression of A
SIRT-1, and Flotillin-1 (a). Altogether, our results demonstrated that miR
with its 3’-UTR, and then the protein expression of its downstream gen
experiments. *P < 0.05, **P < 0.01interacting with its 3’-UTR, and then the protein expres-
sion of its downstream genes.
miR-3908 suppresses cell growth and clonogenicity in
MCF-7 cells
For evaluating the overexpressed or underexpressed pos-
sible biotic outcomes induced by miR-3908, several
functional experiments were performed in MCF-7 cells.
Compared with control cells, proliferation of MCF-7
cells (Fig. 3a) would be inhibited when they were trans-
fected with miR-3908. Moreover, the inhibitors of miR-
3908 accentuated the same process of MCF-7 cells
(Fig. 3a). These results demonstrated that miR-3908
suppressed the proliferation of MCF-7 cells.
Furthermore, the colony formation assay revealed that
miR-3908 played a significant role in the suppression of
proliferative ability compared with the control group in
MCF-7 cells. However, downregulation of miR-3908To verify the miR-3908 effect on the mRNA and protein expression of
e quantification analyses with qRT-PCR and Western blots, respectively.
ll as the protein expression of AdipoR1 (b). Moreover, miR-3908 did not
pression of AMPK, p-AMPK, SIRT-1, and Flotillin-1 also decreased (b).
dipoR1 in MCF-7 cells, but did not affect the mRNA expression of AMPK,
-3908 directly regulates the expression of AdipoR1 by interacting
es. The data are presented as means ± SD from three independent
Fig. 3 miR-3908 suppresses cell growth and clonogenicity in MCF-7
cells. For evaluating the overexpressed or underexpressed possible
biotic outcomes induced by miR-3908, several functional experiments
were performed in MCF-7 cells. Compared with control cells,
proliferation of MCF-7 cells (a) would be suppressed by transfection
with miR-3908. Moreover, the inhibitors of miR-3908 accentuated
the same process in MCF-7 cells (a). Furthermore, the colony
formation assay revealed that miR-3908 played a significant
role in the suppression of this ability compared with the
control group in MCF-7 cells. However, downregulation of
miR-3908 facilitated significantly the colony-forming ability
of MCF-7 cells. These results suggested that miR-3908 also
lowered colony formation of MCF-7 cells (b) (P < 0.001). The
data are presented as means ± SD from three independent
experiments. *P < 0.05, **P < 0.01
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MCF-7 cells. These results suggested that miR-3908
also lowered colony formation of MCF-7 cells (Fig. 3b)
(P < 0.001).miR-3908 suppresses migration of MCF-7 cells
miR-3908 inhibited significantly the migration ability
of MCF-7 cells compared to control in vitro (Fig. 4;
P < 0.001). Conversely, using the inhibitors of miR-
3908, the migration ability was enhanced in MCF-7
cells (Fig. 4). These results suggested that miR-3908
suppresses the migration ability and invasion of MCF-
7 cells.AdipoR1 protein interacted with Flotillin-1
The proteins that interacted with AdipoR1 were ana-
lyzed by CO-IP (co-immunoprecipitation) and confocal
laser scanning microscopy (CLSM). MCF-7 cells were
harvested after 48 h in culture, then total cellular pro-
teins extracted and CO-IP’d (co-immunoprecipitated)
with anti-AdipoR1 antibodies followed by anti-Flotillin-1
antibodies (Fig. 5a). Then, the above proteins were then
Co-IP’d with anti-Flotillin-1 antibodies followed by
AdipoR1 antibodies (Fig. 6a). AdipoR1 is localized to the
cell membrane of MCF-7 cells. After MCF-7 cells were
co-transfected with plasmids pEGFP-C1-Flotillin-1
(green) and pDS-RED1-N1-AdipoR1 (red) for 48 h, the
confocal scanning images demonstrated that the
Flotillin-1 recombinant protein was localization to the
cell membrane. The nuclei of the cells (blue) were
stained by DAPI. The overlaid image indicates that
AdipoR1 overlapped with Flotillin-1 at the cell mem-
brane (Fig. 5b). These results demonstrated that
AdipoR1 protein may interact with Flotillin-1 at the cell
membrane of MCF-7 cells.
The inhibitors of miR-3908 induced mobility of AdipoR1
into lipid rafts
In the last few years, many researches have indicated
that functional receptors assemble at the platforms pro-
vided by lipid rafts. In metastasis and progression of BC,
AdipoR1 plays an important role, and may be a potential
alternative therapeutic goal for patients with BC [28].
The migration of AdipoR1 into lipid rafts plays an im-
portant role in anti-invasion process. To explore the
anti-invasion functions of miR-3908 inhibitors, the role
of these inhibitors on the mobility of AdipoR1 into lipid
rafts was determined. Our results demonstrated that
miR-3908 inhibitors reduced the migration of AdipoR1
into fractions of the lipid raft. The phenomenon could
be enhanced by miR-3908, but reversed by inhibitors of
miR-3908 as well as by Flotillin-1 (Fig. 6).
Discussion
The mechanism for the transcriptional control of gene
expression associated with BC has been explored.
Although it is well known that there are several different
angiogenetic mechanisms, it is still unclear how miRNA
modulates lipid raft-mediated angiogenesis. A number of
factors, such as miRNAs, play a crucial role in modulat-
ing gene expression, such as those involved in BC [29].
miRNAs are involved in the physiological processes of
cells; however, deregulation of them may be related to
cancer. Many miRNAs in BC exhibit a different expres-
sion level from normal human breast tissues. Further-
more, in BC, a few miRNAs have been identified that
are correlated with tumor subtype, therapy response,
and pathology phenotype. As drug resistance in patients
Fig. 4 miR-3908 suppresses migration of MCF-7 cells. miR-3908 inhibited significantly the migration ability of MCF-7 cells compared to control
(NC) (a and b) in vitro (P < 0.001). Conversely, using the inhibitors of miR-3908, the migration ability was enhanced in MCF-7 cells (a and b). These
results suggested that miR-3908 suppresses the migration of MCF-7 cells. The data are presented as means ± SD from three independent experi-
ments. *P < 0.05, **P < 0.01
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biomarker for the prediction of fresh targets for BC
treatment. In the present work, we ascertained the novel
miRNA, miR-3908, and investigated its effects and
meanings in the developmental process of BC.
Adipose tissue secretes an adipokine called adipo-
nectin, which is downexpressed in obesity with
insulin-resistance. Its biological effects are performed
by its receptors AdipoR1 and AdipoR2. AdipoR1 may
upregulate the expression of AMPK (adenosine
monophosphate-activated protein kinase), and PPAR
(peroxisome proliferator-activated receptor)-α may be
activated by AdipoR2 [30]. However, the miRNA-
mediated regulation of AdipoR1 activity during the
developmental process of BC remains poorly
understood.
As shown in the current study, our bioinformatics
analysis, using online software (http://targetscan.org/),
confirmed that the 3’-UTR site of AdipoR1 mRNA is
complimentary to miR-3908. The results of luciferase
reporter analysis indicated that the relative activity of
AdipoR1 3’-UTR significantly decreases in MCF-7 cells
transfected with miR-3908, but there were no changes in
the mut-AdipoR1 group. Moreover, it was identified that
miR-3908 could not form direct bonds with AMPK,
SIRT-1, or Flotillin-1 3’-UTRs, respectively. Followingoverexpression of miR-3908 in MCF-7 cells compared to
NC, Western blot analyses verified that protein expres-
sion levels of AdipoR1 downregulated in MCF-7 cells
induced by miR-3908. Furthermore, miR-3908 did not
affect the mRNA expression of AMPK, SIRT-1, and
Flotillin-1, but the protein expression of AMPK, p-
AMPK, SIRT-1, and Flotillin-1 also decreased. These
outcomes verified that the mRNA of AdipoR1 is the dir-
ect target of miR-3908, and suppresses protein expres-
sion of its downstream pathway genes, including AMPK,
p-AMPK, and SIRT-1. Therefore, this provides a new
therapy target for BC treatment.
For evaluating the possible biotic outcomes induced by
miR-3908, we overexpressed or underexpressed miR-
3908, and then performed a few functional experiments
related to the molecular functions of MCF-7 cells. Sub-
sequently, MCF-7 cells were exposed to the mimics or
inhibitors of miR-3908, and then the cell functions of
MCF-7 cells, such as proliferation, colony formation,
and migration, were analyzed. These results demon-
strated that miR-3908 suppressed the proliferation of
MCF-7 cells, lowered its colony formation, and re-
strained its ability to influence cell migration.
The changes in BC cells conducive to tumor evolution,
heterogeneity, metastasis, and ultimately, drug resistance
are shaped by numerous genetic changes including
Fig. 5 AdipoR1 protein interacted with Flotillin-1. The proteins that
interacted with AdipoR1 were analyzed by co-immunoprecipitation
(CO-IP) and confocal laser scanning microscopy (CLSM). MCF-7 cells
were harvested after 48 h in culture, then total cellular proteins were
extracted and CO-IP’d (co-immunoprecipitated) with anti-AdipoR1
antibodies followed by anti-Flotillin-1 antibodies (a). Then, the above
proteins were then Co-IP’d with anti-Flotillin-1 antibodies followed
by AdipoR1 antibodies (a). AdipoR1 is localized to the cell mem-
brane of EC. After MCF-7 cells were co-transfection with plasmids
pEGFP-C1-Flotillin-1 (green) and pDS-RED1-N1-AdipoR1 (red) for 48 h,
the confocal scanning images demonstrated that the Flotillin-1
recombinant protein was localization to the cell membrane.
The nuclei of the cells (blue) were stained by DAPI. The overlaid
image indicates that AdipoR1 overlapped with Flotillin-1 at the
MCF-7 cell membrane (b)
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mediary metabolic pathways such as amino acid synthe-
sis, oxidative phosphorylation, the citric acid cycle,
glycolysis, and lipid metabolism [31].
There is extensive evidence showing that the metabol-
ism of both exogenous and endogenous substances
influences BC growth. Moreover, it is clear that metab-
olism can influence each unique BC subclass in diverse
ways and to varying degrees. These metabolic changes
have been categorized in an assortment of ways; for
example, many involve changes in energy metabolism
such as in the way that glucose, amino acids, and lipids
are processed [31]. Profound advances have been made
towards comprehending the changes in genetic informa-
tion that occur during BC development, particularly in
the area of cancer metabolism. Furthermore, cancer
metabolism traditionally refers to intermediary metabol-
ism and generally does not include other cellular
metabolic-related pathways and processes such as drugmetabolism. However, alterations in drug-metabolizing
enzymes and metabolite transporters play important
roles in oncogenesis and drug resistance. New insights
into the differential expression patterns of metabolic
enzymes between ER-positive and ER-negative BC have
the strong potential to guide rational development of
novel therapeutic agents and to reshape current treat-
ment regimens for optimal outcomes [31].
In addition, the expression patterns of many meta-
bolic enzymes change as tumors become more aggres-
sive and metastatic. Although, it is less clear, it
appears that chemotherapy alters the metabolic
phenotype of cancer cells which may offer a thera-
peutic opportunity [32]. Therefore, novel agents and
approaches are needed that harness metabolic differ-
ences in BC which set them apart from normal tis-
sues. For example, delivering small molecules or
peptides via nanoparticles is an exciting therapeutic
approach because of their ability to target specific cell
types and organelles such as mitochondria [33–35].
Paulmurugan et al. recently published a report where
they delivered the FASN (fatty acid synthase) inhibitor
orlistat to TNBC (triple-negative breast cancer) via
folate-decorated polymeric nanoparticles leading to
enhanced cytotoxicity [36]. Another emerging thera-
peutic target in BC that may account for the intratu-
moral heterogeneity seen in patients’ tumors are
BCSCs (breast cancer stem cells). As noted, BCSCs
are heavily glycolytic and may influence the metabolic
phenotype of the tumor. A variety of pharmacologic
agents for targeting these cells are at varying stages
of development.
MiRNAs play a significant role in the functional regu-
lation of MCF-7 cells. MiRNAs are coincidentally men-
tioned to modulate genetic expression in all types of
cancer cells by regulating extensive processes in biology
related to the progression and development of tumors
such as cell differentiation, apoptosis, and proliferation.
Previous studies indicate that miRNAs act as oncogenic
or oncosuppressive miRNA to promote or inhibit BC
tumorigenesis and progression, and may be conducive to
the diagnosis and treatment of BC [37]. Lipid rafts make
up membrane microdomains which are the platforms of
a kind of signaling molecule. Compared to the surround-
ing membrane, these microdomains are more tightly
packed and ordered [38]. In recent times, many re-
searches have demonstrated that many functional recep-
tors were assembled on the platforms provided by lipid
rafts [39]. Flotillin-1 protein localizes to caveolae and
plays an important role in cell morphology and vesicle
trafficking [40]. The proteins that interacted with
AdipoR1 were analyzed by CO-IP and CLSM. Our
results indicated that AdipoR1 protein may interact with
Flotillin-1 at the cell membrane of MCF-7 cells.
Fig. 6 The inhibitors of miR-3908 induced the mobility of AdipoR1 into lipid rafts. In the last few years, many researches have indicated that functional
receptors assemble at the platforms provided by lipid rafts. In metastasis and progression of breast cancer (BC), AdipoR1 plays an important role,
and may be a potential alternative therapeutic goal for patients with BC. The migration of AdipoR1 into lipid rafts plays an important role
in the anti-invasion process. To explore the anti-invasion functions of miR-3908 inhibitors, the role of these inhibitors on the mobility of
AdipoR1 into lipid rafts was determined. Our results demonstrated that miR-3908 inhibitors reduced the migration of AdipoR1 into fractions of the lipid
raft. The phenomenon could be enhanced by miR-3908, but reversed by inhibitors of miR-3908 as well as by Flotillin-1
Li et al. World Journal of Surgical Oncology  (2017) 15:69 Page 9 of 10It is known that AdipoR1 plays an important role in,
and may be a potential alternative therapeutic goal for,
patients with BC. The migration of AdipoR1 into lipid
rafts play an important role in the anti-migration
process. Our results demonstrated that miR-3908 inhibi-
tors reduced the mobility of AdipoR1 into the fractions
of the lipid raft. Moreover, miR-3908 could enhance its
migration, but the phenomenon was reversed by inhibi-
tors of miR-3908 as well as by Flotillin-1. miR-3908 sup-
pressed the interaction between AdipoR1 and Flotillin-1
by inhibiting the expression of the AdipoR1 or AMPK/
SIRT1 signaling pathway. Furthermore, the packages of
lipid rafts were blocked and migration of MCF-7 cells
was restrained.Conclusions
In summary, we have illustrated miR-3908, which spe-
cifically binds to AdipoR1 mRNA 3’-UTR. miR-3908
has effects on the biological functions of MCF-7 cells
such as cell proliferation, colony formation, and mi-
gration. Moreover, AdipoR1 is a crucial mediator of
migration in MCF-7 cells through inhibiting the
AMPK/SIRT-1 signaling pathway. Lipid rafts regulate
the interactions between AdipoR1 and Flotillin-1, and
then the migration process associated with miR-3908
in MCF-7 cells. Our findings suggest that targeting
miR-3908 and the lipid raft, being involved in BC cell
migration, is a hopeful method for the prevention and
treatment of BC.Abbreviations
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miRNAs: MicroRNAs; NC: Negative control; PMSF: Phenylmethanesulfonyl
fluoride; PPAR: Peroxisome proliferator-activated receptor; PVDF: Polyvinylidene
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